Risk factors, prevention and treatment of weight gain associated with the use of antidepressants and antipsychotics: a state-of-the-art clinical review — Marco Solmi (2024) | RDL Network
Risk factors, prevention and treatment of weight gain associated with the use of antidepressants and antipsychotics: a state-of-the-art clinical review
Article 2024 en
Authors
MS
Marco Solmi
AM
Alessandro Miola
FC
Federico Capone
Abstract
1 min read
To prevent, manage, and treat antidepressant/antipsychotic-related weight gain, we recommend i) assessing risk factors for obesity before treatment, ii) monitoring metabolic health at baseline and regularly during follow-up, iii) offering lifestyle interventions including regular exercise and healthy diet based on patient preference to optimize motivation, iv) considering first-line psychotherapy for mild-moderate depression and anxiety disorders, v)choosing medications based on medications' and patient's weight gain risk, vi) choosing medications based on acute vs long-term treatment, vii) using effective, tolerated medications, viii) switching to less weight-inducing antipsychotics/antidepressants where possible, ix) using early weight gain as a predictor of further weight gain to inform the timing of intervention/switch options, and x) considering adding metformin or glucagon-like peptide-1 receptor agonists, or topiramate(second-line due to potential adverse cognitive effects) to antipsychotics, or aripiprazole to clozapine or olanzapine.
Marco Solmi, Andréa Murru, Isabella Pacchiarotti, Juan Undurraga, Nicola Veronese, Michele Fornaro, Brendon Stubbs, Francesco Monaco, Eduard Vieta, Mary V. Seeman, Christoph U. Correll, André F. Carvalho
Marco Solmi, Giovanni Croatto, Arnav Gupta, Nicholas Fabiano, Stanley Wong, Michele Fornaro, Lynne Kolton Schneider, S. Christy Rohani-Montez, Leanne Fairley, Nathalie Smith, István Bitter, Philip Gorwood, Heidi Taipale, Jari Tiihonen, Samuele Cortese, Elena Dragioti, Ebba Du Rietz, René Ernst Nielsen, Joseph Firth, Paolo Fusar‐Poli, Catharina A. Hartman, ,
Discussion(0)
No comments yet. Be the first to comment.